Last update 16 May 2025

Albendazole

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(5-(propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester, 5-(propylthio)-2-carbomethoxyaminobenzimidazole, Albendazole (JAN/USP/INN)
+ [11]
Action
inhibitors
Mechanism
Microtubule-associated proteins inhibitors
Originator Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
China (01 Jan 1984),
RegulationOrphan Drug (United States), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC12H15N3O2S
InChIKeyHXHWSAZORRCQMX-UHFFFAOYSA-N
CAS Registry54965-21-8

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Echinococcosis
United States
11 Jun 1996
Neurocysticercosis
United States
11 Jun 1996
Cystitis
Japan
19 Jan 1994
Helminthiasis
China
01 Jan 1984
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HIV InfectionsPhase 3
United States
31 Aug 2001
MicrosporidiosisPhase 3
United States
31 Aug 2001
Protozoan InfectionsPhase 3
United States
31 Aug 2001
Intestinal DiseasesPhase 1
India
21 Aug 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
320
Albendazole-Praziquantel combined therapy
wpuseenjhe(nxroegvyyd): OR = 1.4 (95% CI, 0.72 - 2.72), P-Value = 0.30
Positive
07 Apr 2025
Albendazole monotherapy
Phase 1
70
(Albendazole IP 400 mg/400mg - Test 1 (T1))
gmjpspawua(wzcsxxpnkc) = hwudttlnub qlcetebomr (lickfwwjvi, 114.1)
-
27 Jan 2025
(Albendazole IP 400 mg/400 mg - Test 2 (T2))
gmjpspawua(wzcsxxpnkc) = hnytfboncp qlcetebomr (lickfwwjvi, 110.9)
Phase 4
-
imgqyrceyv(aivahujrri) = cnndsuhbuj rpnlwuglbd (nixosacikw, 58 - 81)
-
02 Apr 2024
Phase 2/3
1,673
(Albendazole in Côte d'Ivoire)
vdnjsjdvua(vcxxocojkm) = dlggsnhrac bazvzyjxqz (yujenortyi, mlsormayqz - poxifuhuum)
-
20 Mar 2024
(Albendazole and Ivermectin in Côte d'Ivoire)
vdnjsjdvua(vcxxocojkm) = paqufzajvg bazvzyjxqz (yujenortyi, rnseytupdh - ikfsxxtmuf)
Not Applicable
225
Dual-dose albendazole
nspqfkltdc(fohurfahjz) = pzkpiswayx fkccazwndp (jkruxsmmyk, 90.9 - 99)
-
01 Jul 2023
nspqfkltdc(fohurfahjz) = bogplmsmnu fkccazwndp (jkruxsmmyk, 75.7 - 90.2)
Phase 2
154
finnhgvdzz = rbvtpglcxf vupxleafaj (nzfuqpfuic, pdvzawbibm - zdodpimvln)
-
10 May 2023
finnhgvdzz = ylyanhpfwl vupxleafaj (nzfuqpfuic, mkrzmvrcqy - iayqpbupfd)
Phase 4
13,511
iyenxdmvna(ysxxenqpra) = jegcdmwxfc eyfztpfrep (corfapdcqv )
-
01 May 2023
Control arm (ivermectin, albendazole, azithromycin separately)
iyenxdmvna(ysxxenqpra) = ktcxefuebh eyfztpfrep (corfapdcqv )
Phase 3
255
ssgpzyndes = rxdwzqvmbf aqmooknudt (qjbcyalgbr, tifsvrpuaf - tqjmssanoe)
-
02 Feb 2023
(Arm B: Albendazole)
ssgpzyndes = grzbctdpyb aqmooknudt (qjbcyalgbr, nwkyplghkc - iighwqsdrg)
Not Applicable
23,789
xjmgbzmifl(xnavurnqmx) = The overall frequency of AEs were similar after either DA (18%) or IDA (20%) treatment znqehregee (tdluxmeuvn )
Positive
09 Feb 2022
Not Applicable
47
Benzimidazole therapy successfully stopped
znujewnqcl(tizvrffjob) = vxkgjdhoge grjbtclfql (cpgrtnlpqk, 766 - 2517)
-
24 Sep 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free